In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Yong ^a,b   Hu, Zhiqing ^a   Li, Zhuo ^a   Pang, Jialun ^a   Feng, Mai ^a   Hu, Xuyun ^a   Wang, Xiaolin ^a   Lin Peng, Siyuan ^c   Liu, Bo ^a   Chen, Fangping ^b   Wu, Lingqian ^a,c   Liang, Desheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Jiahui Genetics Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CRE RECOMBINASE; INTEGRASE; STOP CODON; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE;

BIOSYNTHESIS; BLOOD; CELL DIFFERENTIATION; CHEMISTRY; CHROMOSOME INVERSION; CYTOLOGY; ENDOTHELIUM CELL; EXON; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HEMOPHILIA A; HOMOLOGOUS RECOMBINATION; HUMAN; INDUCED PLURIPOTENT STEM CELL; INTRON; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIMARY CELL CULTURE; PROCEDURES; PROMOTER REGION; SECRETION (PROCESS); STOP CODON;

BASE SEQUENCE; CELL DIFFERENTIATION; CODON, NONSENSE; ENDOTHELIAL CELLS; EXONS; FACTOR VIII; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA A; HOMOLOGOUS RECOMBINATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INTEGRASES; INTRONS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PRIMARY CELL CULTURE; PROMOTER REGIONS, GENETIC; SEQUENCE INVERSION; TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES;

EID: 84953897602     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18865     Document Type: Article

References (48)

1. Chuah, M. K., Nair, N. & VandenDriessche, T. Recent progress in gene therapy for hemophilia. Hum. Gene Ther. 23, 557-565 (2012).
2. Graw, J. et al. Haemophilia A: from mutation analysis to new therapies. Nat. Rev. Genet. 6, 488-501 (2005).
3. Vehar, G. A. et al. Structure of human factor VIII. Nature 312, 337-342 (1983).
4. Nathwani, A. C. et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. New Engl. J. Med. 365, 2357-2365 (2011).
5. Bolton-Maggs, P. H. B. & Pasi, K. J. Haemophilias a and b. Lancet 361, 1801-1809 (2003).
6. Lakich, D. et al. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat. Genet. 5, 236-241 (1993).
7. De Brasi, C. D. & Bowen, D. J. Molecular characteristics of the intron 22 homologs of the coagulation factor VIII gene: an update. J. Thromb. Haemost. 6, 1822-1824 (2008).
8. Rossetti, L. C., Radic, C. P., Larripa, I. B. & De Brasi, C. D. Developing a new generation of tests for genotyping hemophilia-causative rearrangements involving int22h and int1h hotspots in the factor VIII gene. J. Thromb. Haemost. 6, 830-836 (2008).
9. Zhou, T. et al. Generation of induced pluripotent stem cells from urine. J. Am. Soc. Nephrol. 22, 1221-1228 (2011).
10. Dorrenhaus, A. et al. Cultures of exfoliated epithelial cells from different locations of the human urinary tract and the renal tubular system. Arch. Toxicol. 74, 618-626 (2000).
11. Sander, J. D. et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat. Biotechnol. 29, 697 (2011).
12. Kim, Y., Kweon, J. & Kim, J. S. TALENs and ZFNs are associated with different mutation signatures. Nat. Methods. 10, 185-185 (2013).
13. Fine, E. J. et al. An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res. 42, e42-e42 (2014).
14. Matsui, H. et al. Delivery of Full-Length Factor VIII Using a piggyBac Transposon Vector to Correct a Mouse Model of Hemophilia A. PloS One 9, e104957 (2014).
15. Choi, K. D. et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 27, 559-567 (2009).
16. Pandey, G. S. et al. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A. Nat. Med. 19, 1318-1324 (2013).
17. Sauna, Z. E. et al. The intron-22-inverted F8 locus permits intracellular factor VIII synthesis, explaining its low inhibitor risk and suggesting a role for pharmacogenomics. Blood 125, 223-228 (2015).
18. Sanada, C. et al. Mesenchymal stem cells contribute to endogenous FVIII: c production. J. Cell Physiol. 228, 1010-1016 (2013).
19. Pittenger, M. F. et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147 (1999).
20. Lai, R. C., Choo, A. & Lim, S. K. In Mesenchymal stem cell assays and applications 1st edn, Vol. 698 (eds Vemuri, M. C. et al.) Ch. 11, 141-150 (Springer, 2011).
21. Chuah, M. K. L. et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101, 1734-1743 (2003).
22. Connelly, S. et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281 (1998).
23. Balague, C. et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95, 820-828 (2000).
24. Du, L. M. et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat. Commun. 4, 2773 (2013).
25. Park, C. Y. et al. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proc. Natl. Acad. Sci. USA 111, 9253-9258 (2014).
26. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007).
27. Liu, X. et al. Targeting of the human coagulation factor IX gene at rDNA locus of human embryonic stem cells. PloS One 7, e37071 (2012).
28. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011).
29. Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651 (2005).
30. Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011).
31. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
32. Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. USA 93, 1156-1160 (1996).
33. Wu, Y. et al. TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. Biochem. Bioph. Res. Co. 446, 261-266 (2014).
34. Chen, S. et al. A large-scale in vivo analysis reveals that TALENs are significantly more mutagenic than ZFNs generated using context-dependent assembly. Nucleic Acids Res. 41, 2769-2778 (2013).
35. Shahani, T. et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J. Thromb. Haemost. 12, 36-42 (2014).
36. Shahani, T. et al. Activation of human endothelial cells from specific vascular beds induces the release of a FVIII storage pool. Blood 115, 4902-4909 (2010).
37. Jacquemin, M. et al. FVIII production by human lung microvascular endothelial cells. Blood 108, 515-517 (2006).
38. Shi, Q. et al. Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. Blood 116, 3049-3057 (2010).
39. Shiltagh, N. et al. Solution structure of the major factor VIII binding region on von Willebrand factor. Blood 123, 4143-4151 (2014).
40. Tuddenham, E. In search of the source of factor VIII. Blood 123, 3691-3691 (2014).
41. Fahs, S. A., Hille, M. T., Shi. Q., Weiler, H. & Montgomery, R. R. A conditional knockout mouse model revealsendothelial cells as the predominant and possibly exclusivesource of plasma factor VIII. Blood 123, 3706-3713 (2014).
42. Everett, L. A., Cleuren, A. C. A., Khoriaty, R. N. & Ginsburg, D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123, 3697-3705 (2014).
43. Xu, D. et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc. Natl. Acad. Sci. USA 106, 808-813 (2009).
44. Porada, C. D. et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp. hematol. 39, 1124-1135 (2011).
45. Follenzi, A. et al. Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 119, 5532-42 (2012).
46. Wang, L. et al. Generation of integration-free neural progenitor cells from cells in human urine. Nat. Method. 10, 84-89 (2013).
47. Guschin, D. Y. et al. in Engineered zinc finger proteins 1st edn, Vol. 649 (eds Mackay, J. P. & Segal, D. J.) Ch. 15, 247-256 (Springer, 2010).
48. Liu, X. et al. Non-viral ex vivo transduction of human hepatocyte cells to express factor VIII using a human ribosomal DNA-targeting vector. J. Thromb. Haemost. 5, 347-351 (2007).